EWTX8:00 AMEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesedgewisetx.com
EWTX7:00 AMEdgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)Trial Results • Phase 2edgewisetx.com
EWTX4:01 PMEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesedgewisetx.com
EWTX8:30 AMEdgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipelineedgewisetx.com
EWTX8:00 AMEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026edgewisetx.com
EWTX8:00 AMEdgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indicationsedgewisetx.com
EWTX8:00 AMEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rulesedgewisetx.com